Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Oligometastatic Breast Cancer - a Randomised Phase 3 Trial Comparing Stereotactic Ablative Radiotherapy and Systemic Treatment With Systemic Treatment Alone as 1st Line Treatment

NCT05377047 is registered in ClinicalTrials.gov with Vastra Gotaland Region as lead sponsor.

NCT NCT05377047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05377047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Oligometastatic Breast Cancer - a Randomised Phase 3 Trial Comparing Stereotactic Ablative Radiotherapy and Systemic Treatment With Systemic Treatment Alone as 1st Line Treatment
Lead sponsor
Vastra Gotaland Region
Phase
Phase 3
Overall status
Recruiting
Start date
September 19, 2022
Completion date
December 31, 2030
Enrollment
345 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage iv, oligometastatic disease